AAAAAA
Results: 1-25/26
Authors:
Heinzer, H
Huland, E
Huland, H
Citation: H. Heinzer et al., Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer, WORLD J URO, 19(2), 2001, pp. 111-119
Authors:
Shurin, GV
Aalamian, M
Pirtskhalaishvili, G
Bykovskaia, S
Huland, E
Huland, H
Shurin, MR
Citation: Gv. Shurin et al., Human prostate cancer blocks the generation of dendritic cells from CD34+hematopoietic progenitors, EUR UROL, 39, 2001, pp. 37-40
Authors:
Friedrich, MG
Riethdorf, S
Erbersdobler, A
Tiemer, C
Schwaibold, H
Solter, JK
Huland, E
Riethdorf, L
Conrad, S
Hammerer, PG
Huland, H
Citation: Mg. Friedrich et al., Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder, EUR UROL, 39(2), 2001, pp. 159-166
Authors:
Aalamian, M
Pirtskhalaishvili, G
Nunez, A
Esche, C
Shurin, GV
Huland, E
Huland, H
Shurin, MR
Citation: M. Aalamian et al., Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells, PROSTATE, 46(1), 2001, pp. 68-75
Authors:
Huland, E
Citation: E. Huland, Interleukin-2 and cancer - Physiological and pharmacological uses, FOL BIOL, 47(4), 2001, pp. 111-112
Authors:
Huland, E
Heinzer, H
Huland, H
Citation: E. Huland et al., Overview of interleukin-2 inhalation therapy, CA J SCI AM, 6, 2000, pp. S104-S112
Authors:
Atzpodien, J
Huland, E
Heinzer, H
Citation: J. Atzpodien et al., Foundation of the German Society for Immunotherapy: Significant advances in cancer treatment, ONKOLOGIE, 23(5), 2000, pp. 476-477
Authors:
Bubenik, J
Den Otter, W
Huland, E
Citation: J. Bubenik et al., Local cytokine therapy of cancer: interleukin-2, interferons and related cytokines, CANCER IMMU, 49(2), 2000, pp. 116-122
Authors:
Heinzer, H
Huland, E
Huland, H
Citation: H. Heinzer et al., Treatment of metastatic renal cell carcinoma. Immunotherapy versus surgical removal, UROLOGE A, 39(4), 2000, pp. 356-361
Authors:
Hilz, H
Graefen, M
Noldus, J
Hammerer, P
Knabbe, C
Huland, E
Huland, H
Citation: H. Hilz et al., Advanced prostate cancer is associated with a decrease in serum luteinizing hormone, EUR UROL, 38(3), 2000, pp. 243-249
Authors:
Hammerer, P
Graefen, M
Henke, RP
Haese, A
Palisaar, J
Huland, E
Huland, H
Citation: P. Hammerer et al., Analysis of molecular isoforms of PSA and their ratios in men with PSA-relapse after radical prostatectomy, ANTICANC R, 20(6D), 2000, pp. 5253-5255
Authors:
Hautmann, S
Huland, E
Wullbrand, A
Friedrich, M
Huland, H
Citation: S. Hautmann et al., Treatment of metastatic hormone-refractory prostate adenocarcinoma (MatLyLu) in Copenhagen rats with micro-osmotic interleukin-2 pumps, ANTICANC R, 20(6B), 2000, pp. 4495-4498
Authors:
Hautmann, S
Huland, E
Grupp, C
Haese, A
Huland, H
Citation: S. Hautmann et al., Super-sensitive prostate-specific antigen (PSA) in serum of women with benign breast disease or breast cancer, ANTICANC R, 20(3B), 2000, pp. 2151-2154
Authors:
Haese, A
Becker, C
Noldus, J
Graefen, M
Huland, E
Huland, H
Lilja, H
Citation: A. Haese et al., Human glandular kallikrein 2: A potential serum marker for predicting the organ confined versus nonorgan confined growth of prostate cancer, J UROL, 163(5), 2000, pp. 1491-1497
Authors:
Friedrich, MG
Erbersdobler, A
Schwaibold, H
Conrad, S
Huland, E
Huland, H
Citation: Mg. Friedrich et al., Detection of loss of heterozygosity in the p53 tumor-suppressor gene with PCR in the urine of patients with bladder cancer, J UROL, 163(3), 2000, pp. 1039-1042
Authors:
Huland, E
Heinzer, H
Huland, H
Citation: E. Huland et al., A comparison of systemic versus inhaled recombinant IL-2 administration for the treatment of metastatic renal cell carcinoma, FOL BIOL, 46(6), 2000, pp. 241-250
Authors:
Huland, E
Heinzer, H
Citation: E. Huland et H. Heinzer, Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, alpha-interferon (leucocyte) and tamoxifen, BR J CANC, 82(1), 2000, pp. 246-246
Authors:
Heinzer, H
Mir, TS
Huland, E
Huland, H
Citation: H. Heinzer et al., Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy, J CL ONCOL, 17(11), 1999, pp. 3612-3620
Authors:
Heinzer, H
Huland, E
Aalamian, M
Huland, H
Citation: H. Heinzer et al., Treatment of pulmonary metastases from kidney cell carcinoma with inhalational interleukin-2. 10-year experience Hamburger Unicenter, UROLOGE, 38(5), 1999, pp. 466-473
Authors:
Graefen, M
Noldus, J
Pichlmeier, U
Haese, A
Hammerer, P
Fernandez, S
Conrad, S
Henke, RP
Huland, E
Huland, H
Citation: M. Graefen et al., Early prostate-specific antigen relapse after radical retropubic prostatectomy: Prediction on the basis of preoperative and postoperative tumor characteristics, EUR UROL, 36(1), 1999, pp. 21-30
Authors:
Haese, A
Huland, E
Graefen, M
Huland, H
Citation: A. Haese et al., Supersensitive PSA-analysis after radical prostatectomy: A powerful tool to reduce the time gap between surgery and evidence of biochemical failure, ANTICANC R, 19(4A), 1999, pp. 2641-2644
Authors:
Hautmann, SH
Huland, E
Huland, H
Citation: Sh. Hautmann et al., Local intratumor immunotherapy of prostate cancer with interleukin-2 reduces tumor growth, ANTICANC R, 19(4A), 1999, pp. 2661-2663
Authors:
Huland, E
Heinzer, H
Huland, H
Citation: E. Huland et al., Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2), ANTICANC R, 19(4A), 1999, pp. 2679-2683
Authors:
Huland, E
Heinzer, H
Huland, H
Citation: E. Huland et al., Immunotherapy of pulmonary metastatic renal cell carcinoma: Success dependant on risk factors?, HEP-GASTRO, 46, 1999, pp. 1257-1262
Authors:
Lilja, H
Haese, A
Bjork, T
Friedrich, MG
Piironen, T
Pettersson, K
Huland, E
Huland, H
Citation: H. Lilja et al., Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy, J UROL, 162(6), 1999, pp. 2029-2034